{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:28:28Z","timestamp":1789522108740,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>CD19 is a cell surface protein that is found on both healthy and malignant B cells. Accordingly, it has become an important target for novel treatments for non-Hodgkin lymphomas and B-cell leukaemia. Three anti-CD19 monoclonal antibodies with distinct mechanisms of action have been developed for the treatment of B-cell malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reviewed the preclinical and clinical data on the development of the newly approved anti-CD19 monoclonal antibodies blinatumomab, tafasitamab and loncastuximab tesirine, and consider their place in the treatment of relapsed or refractory B-cell malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Blinatumomab is a bispecific T-cell engager that binds to both CD19 on B cells and CD3 on T cells, facilitating antibody-dependent cytotoxicity. Blinatumomab significantly prolongs overall survival in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, although cytokine release syndrome and severe neurotoxicity may necessitate discontinuation. Tafasitamab, which has modified anti-CD19 Fab and Fc regions, has significantly enhanced affinity for both CD19 and effector cell receptors compared with unmodified anti-CD19. In L-MIND, tafasitamab plus lenalidomide provided an overall response rate (ORR) of 57.5% in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients non-transplant eligible. Loncastuximab tesirine is an antibody\u2013drug conjugate that has been studied as monotherapy and in combination with ibrutinib in 3L\u2009+\u2009relapsed or refractory DLBCL. The ORR was 48.3% in a phase II trial of loncastuximab tesirine. The optimal place of anti-CD19 monoclonal antibodies in therapy has yet to be determined, but the prospect of improved outcomes for at least some patients with treatment-resistant B-cell malignancies appears likely, particularly in those with limited therapeutic options and poor prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03833-x","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T08:02:43Z","timestamp":1636185763000},"page":"177-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"3833_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1200\/edbk_279043","volume":"40","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Ghosh N, Smith SM (2020) ADCs, BiTEs, CARs, and small molecules: a new era of targeted therapy in non-Hodgkin lymphoma. Am Soc Clin Oncol Educ Book 40:302\u2013313. https:\/\/doi.org\/10.1200\/edbk_279043","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"3833_CR2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63(6):1424\u20131433","journal-title":"Blood"},{"issue":"6","key":"3833_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","volume":"115","author":"FT Awan","year":"2010","unstructured":"Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr et al (2010) CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115(6):1204\u20131213. https:\/\/doi.org\/10.1182\/blood-2009-06-229039","journal-title":"Blood"},{"issue":"9","key":"3833_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ et al (2021) Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325(9):833\u2013842. https:\/\/doi.org\/10.1001\/jama.2021.0669","journal-title":"JAMA"},{"key":"3833_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00139-x","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(21)00139-x","journal-title":"Lancet Oncol"},{"key":"3833_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","volume":"14","author":"R Camicia","year":"2015","unstructured":"Camicia R, Winkler HC, Hassa PO (2015) Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer 14:207. https:\/\/doi.org\/10.1186\/s12943-015-0474-2","journal-title":"Mol Cancer"},{"issue":"4","key":"3833_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","volume":"11","author":"BD Cheson","year":"2021","unstructured":"Cheson BD, Nowakowski G, Salles G (2021) Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J 11(4):68. https:\/\/doi.org\/10.1038\/s41408-021-00456-w","journal-title":"Blood Cancer J"},{"issue":"4","key":"3833_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"9","key":"3833_CR9","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","volume":"61","author":"L Coyle","year":"2020","unstructured":"Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL et al (2020) Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 61(9):2103\u20132112. https:\/\/doi.org\/10.1080\/10428194.2020.1759055","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"3833_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"3833_CR11","unstructured":"Depaus J, Ervin-Haynes A, Bryan L, Magagnoli M, Gritti G, Chao G et al. Interim results of a phase 1\/2 study of loncastuximab tesirine (Lonca) combined with ibrutinib in advanced diffuse large b-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) [abstract EP1284].In: 25th Congress of the European Hematology Association; 12 June 2020; Virtual Meeting 2020"},{"issue":"4","key":"3833_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U (2016) Antibody-drug conjugates\u2013an emerging class of cancer treatment. Br J Cancer 114(4):362\u2013367. https:\/\/doi.org\/10.1038\/bjc.2015.435","journal-title":"Br J Cancer"},{"issue":"4","key":"3833_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I et al (2019) Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther 106(4):781\u2013791. https:\/\/doi.org\/10.1002\/cpt.1396","journal-title":"Clin Pharmacol Ther"},{"key":"3833_CR14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958","author":"J Duell","year":"2021","unstructured":"Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S et al (2021) Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2020.275958","journal-title":"Haematologica"},{"key":"3833_CR15","unstructured":"European Medicines Agency. Blincyto (blinatumomab) [summary of product characteristics] 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf. Accessed 1 May 2021."},{"issue":"5","key":"3833_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51(5):364\u2013369. https:\/\/doi.org\/10.1136\/jcp.51.5.364","journal-title":"J Clin Pathol"},{"issue":"5","key":"3833_CR17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol 182(5):633\u2013643. https:\/\/doi.org\/10.1111\/bjh.15412","journal-title":"Br J Haematol"},{"issue":"10","key":"3833_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/jco.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H et al (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104\u20131111. https:\/\/doi.org\/10.1200\/jco.2014.59.1586","journal-title":"J Clin Oncol"},{"issue":"25","key":"3833_CR19","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/jco.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33(25):2803\u20132811. https:\/\/doi.org\/10.1200\/jco.2014.59.5363","journal-title":"J Clin Oncol"},{"issue":"19","key":"3833_CR20","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA et al (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood 137(19):2634\u20132645. https:\/\/doi.org\/10.1182\/blood.2020007512","journal-title":"Blood"},{"key":"3833_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228553","author":"LJ Harris","year":"2020","unstructured":"Harris LJ, Patel K, Martin M (2020) Novel therapies for relapsed or refractory diffuse large B-cell lymphoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21228553","journal-title":"Int J Mol Sci"},{"key":"3833_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1776255","author":"JA Hartley","year":"2020","unstructured":"Hartley JA (2020) Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. https:\/\/doi.org\/10.1080\/14712598.2020.1776255","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"3833_CR23","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.Can-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY et al (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68(19):8049\u20138057. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2268","journal-title":"Cancer Res"},{"issue":"3","key":"3833_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","volume":"4","author":"N Jain","year":"2020","unstructured":"Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L et al (2020) Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia. Blood Adv 4(3):449\u2013457. https:\/\/doi.org\/10.1182\/bloodadvances.2019000767","journal-title":"Blood Adv"},{"key":"3833_CR25","unstructured":"Jamil A, Mukkamalla SKR. Lymphoma. StatPearls Publishing LLC, Treasure Island, FL. 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560826\/?report=printable. Accessed 1 May 2021."},{"issue":"1","key":"3833_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13256-016-0875-x","volume":"10","author":"W Jurczak","year":"2016","unstructured":"Jurczak W, Bryk AH, Mensah P, Ga\u0142\u0105zka K, Trofimiuk-M\u00fcldner M, Wyrobek \u0141 et al (2016) Single-agent MOR208 salvage and maintenance therapy in a patient with refractory\/relapsing diffuse large B-cell lymphoma: a case report. J Med Case Rep 10(1):123. https:\/\/doi.org\/10.1186\/s13256-016-0875-x","journal-title":"J Med Case Rep"},{"issue":"5","key":"3833_CR27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","volume":"29","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z et al (2018) Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol 29(5):1266\u20131272. https:\/\/doi.org\/10.1093\/annonc\/mdy056","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"3833_CR28","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1182\/blood-2019-124297","volume":"134","author":"W Jurczak","year":"2019","unstructured":"Jurczak W, Zinzani PL, Hess G, Gaidano G, Provencio M, Nagy Z et al (2019) A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma: long-term follow-up, final analysis. Blood 134(Suppl 1):4078. https:\/\/doi.org\/10.1182\/blood-2019-124297","journal-title":"Blood"},{"issue":"23","key":"3833_CR29","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1158\/1078-0432.Ccr-19-0711","volume":"25","author":"BS Kahl","year":"2019","unstructured":"Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E et al (2019) A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 25(23):6986\u20136994. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0711","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3833_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"5","key":"3833_CR31","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3109\/10428194.2013.828354","volume":"55","author":"BZ Katz","year":"2014","unstructured":"Katz BZ, Herishanu Y (2014) Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma 55(5):999\u20131006. https:\/\/doi.org\/10.3109\/10428194.2013.828354","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3833_CR32","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/leu.2012.373","volume":"27","author":"C Kellner","year":"2013","unstructured":"Kellner C, Zhukovsky EA, P\u00f6tzke A, Br\u00fcggemann M, Schrauder A, Schrappe M et al (2013) The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia 27(7):1595\u20131598. https:\/\/doi.org\/10.1038\/leu.2012.373","journal-title":"Leukemia"},{"issue":"5","key":"3833_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000479980","volume":"44","author":"C Kellner","year":"2017","unstructured":"Kellner C, Otte A, Cappuzzello E, Klausz K, Peipp M (2017) Modulating cytotoxic effector functions by Fc engineering to improve cancer therapy. Transfus Med Hemother 44(5):327\u2013336. https:\/\/doi.org\/10.1159\/000479980","journal-title":"Transfus Med Hemother"},{"issue":"9","key":"3833_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T et al (2021) Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325(9):843\u2013854. https:\/\/doi.org\/10.1001\/jama.2021.0987","journal-title":"JAMA"},{"issue":"9","key":"3833_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1358\/dof.2020.45.9.3176880","volume":"45","author":"M Narkhede","year":"2020","unstructured":"Narkhede M, Cheson BD (2020) Tafasitamab. Monoclonal antibody targeting CD19, treatment of B-cell malignancies. Drugs Fut 45(9):641. https:\/\/doi.org\/10.1358\/dof.2020.45.9.3176880","journal-title":"Drugs Fut"},{"issue":"15_suppl","key":"3833_CR36","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2020.38.15_suppl.8020","volume":"38","author":"GS Nowakowski","year":"2020","unstructured":"Nowakowski GS, Rodgers TD, Marino D, Frezzato M, Barbui AM, Castellino C et al (2020) RE-MIND study: a propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 38(15_suppl):8020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8020","journal-title":"J Clin Oncol"},{"issue":"1","key":"3833_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08820130500496878","volume":"35","author":"SH Olejniczak","year":"2006","unstructured":"Olejniczak SH, Stewart CC, Donohue K, Czuczman MS (2006) A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35(1):93\u2013114. https:\/\/doi.org\/10.1080\/08820130500496878","journal-title":"Immunol Invest"},{"issue":"1","key":"3833_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","volume":"30","author":"A Patriarca","year":"2021","unstructured":"Patriarca A, Gaidano G (2021) Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs 30(1):25\u201338. https:\/\/doi.org\/10.1080\/13543784.2021.1855140","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"3833_CR39","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","volume":"189","author":"JC Poe","year":"2012","unstructured":"Poe JC, Minard-Colin V, Kountikov EI, Haas KM, Tedder TF (2012) A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice. J Immunol 189(5):2318\u20132325. https:\/\/doi.org\/10.4049\/jimmunol.1201000","journal-title":"J Immunol"},{"issue":"7","key":"3833_CR40","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/leu.2012.40","volume":"26","author":"S Rafiq","year":"2012","unstructured":"Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC (2012) XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 26(7):1720\u20131722. https:\/\/doi.org\/10.1038\/leu.2012.40","journal-title":"Leukemia"},{"issue":"4","key":"3833_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/antib9040063","volume":"9","author":"S Ro\u00dfkopf","year":"2020","unstructured":"Ro\u00dfkopf S, Eichholz KM, Winterberg D, Diemer KJ, Lutz S, M\u00fcnnich IA et al (2020) Enhancing CDC and ADCC of CD19 antibodies by combining Fc protein-engineering with Fc glyco-engineering. Antibodies (basel) 9(4):63. https:\/\/doi.org\/10.3390\/antib9040063","journal-title":"Antibodies (basel)"},{"issue":"7","key":"3833_CR42","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/s1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21(7):978\u2013988. https:\/\/doi.org\/10.1016\/s1470-2045(20)30225-4","journal-title":"Lancet Oncol"},{"key":"3833_CR43","unstructured":"Sapkota A, Shaikh H. Non-Hodgkin lymphoma. StatPearls Publishing LLC, Treasure Island, FL. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559328\/?report=printable. Accessed 1 May 2021."},{"issue":"Suppl 5","key":"3833_CR44","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A et al (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116\u2013v125. https:\/\/doi.org\/10.1093\/annonc\/mdv304","journal-title":"Ann Oncol"},{"issue":"36","key":"3833_CR45","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/jco.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134\u20134140. https:\/\/doi.org\/10.1200\/jco.2014.56.3247","journal-title":"J Clin Oncol"},{"issue":"1","key":"3833_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"3833_CR47","unstructured":"US Food and Drug Administration. Zynlonta\u2122(loncastuximab tesirine-lpyl) for injection, for intravenous use [prescribing information]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf. Accessed 1 June 2021."},{"key":"3833_CR48","unstructured":"US Food and Drug Administration. Blincyto\u00ae (blinatumomab) for injection, for intravenous use [prescribing information]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125557s008lbl.pdf. Accessed 1 May 2021."},{"key":"3833_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103041","author":"HJ van der Horst","year":"2020","unstructured":"van der Horst HJ, Nijhof IS, Mutis T, Chamuleau MED (2020) Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers12103041","journal-title":"Cancers (basel)."},{"issue":"11","key":"3833_CR50","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N et al (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127(11):1410\u20131416. https:\/\/doi.org\/10.1182\/blood-2015-06-651380","journal-title":"Blood"},{"issue":"11","key":"3833_CR51","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1080\/10428194.2020.1783442","volume":"61","author":"A Viardot","year":"2020","unstructured":"Viardot A, Hess G, Bargou RC, Morley NJ, Gritti G, Goebeler ME et al (2020) Durability of complete response after blinatumomab therapy for relapsed\/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 61(11):2767\u20132770. https:\/\/doi.org\/10.1080\/10428194.2020.1783442","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"3833_CR52","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","volume":"124","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S et al (2014) A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 124(24):3553\u20133560. https:\/\/doi.org\/10.1182\/blood-2014-08-593269","journal-title":"Blood"},{"issue":"16","key":"3833_CR53","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","volume":"113","author":"J Zalevsky","year":"2009","unstructured":"Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR et al (2009) The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113(16):3735\u20133743. https:\/\/doi.org\/10.1182\/blood-2008-10-182048","journal-title":"Blood"},{"issue":"10","key":"3833_CR54","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N et al (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131(10):1094\u20131105. https:\/\/doi.org\/10.1182\/blood-2017-10-813493","journal-title":"Blood"},{"key":"3833_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1471","author":"PL Zinzani","year":"2021","unstructured":"Zinzani PL, Barbui AM, Castellino C, Meli E, Fowler N, Salles G et al (2021) RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1471","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03833-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03833-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03833-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T13:08:46Z","timestamp":1641906526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03833-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3833"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03833-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pier Luigi Zinzani has participated in the speaker bureau for Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, Beigene, has participated in the advisory boards for Verastem, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, Beigene, Sandoz, ADC Therapeutics and served as a consultant to Verastem, MSD, Eusapharma and Novartis. Giorgio Minotti declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}